Clinical Trials Browser

Phase 2/3 × NETWORK × Doxorubicin × Clear all

NCT06820957 2026-02-17

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Phase 2/3 Active not recruiting

Sarcoma, Ewing

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Phase 2/3 Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01189253 2014-08-08

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Phase 2/3 Terminated

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT00060385 2012-09-24

Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 2/3 Terminated

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma